Free Trial

InflaRx (IFRX) Competitors

InflaRx logo
$1.82 +0.13 (+7.69%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$1.82 -0.01 (-0.27%)
As of 05/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IFRX vs. MAZE, SIGA, ZVRA, SAGE, AMLX, PRTA, PRTC, ABVX, TRML, and PGEN

Should you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Maze Therapeutics (MAZE), SIGA Technologies (SIGA), Zevra Therapeutics (ZVRA), Sage Therapeutics (SAGE), Amylyx Pharmaceuticals (AMLX), Prothena (PRTA), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), Tourmaline Bio (TRML), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.

InflaRx vs.

Maze Therapeutics (NASDAQ:MAZE) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Maze Therapeutics has a net margin of 0.00% compared to InflaRx's net margin of -33,362.70%. Maze Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A N/A N/A
InflaRx -33,362.70%-65.98%-56.86%

Maze Therapeutics currently has a consensus target price of $25.67, suggesting a potential upside of 152.38%. InflaRx has a consensus target price of $8.50, suggesting a potential upside of 367.03%. Given InflaRx's higher possible upside, analysts plainly believe InflaRx is more favorable than Maze Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
3.40
InflaRx
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

InflaRx received 238 more outperform votes than Maze Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Maze Therapeutics an outperform vote while only 65.24% of users gave InflaRx an outperform vote.

CompanyUnderperformOutperform
Maze TherapeuticsOutperform Votes
6
100.00%
Underperform Votes
No Votes
InflaRxOutperform Votes
244
65.24%
Underperform Votes
130
34.76%

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Maze Therapeutics has higher revenue and earnings than InflaRx.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M2.66N/AN/AN/A
InflaRx$129.75K941.66-$46.18M-$0.82-2.22

In the previous week, InflaRx had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Maze Therapeutics. InflaRx's average media sentiment score of 0.92 beat Maze Therapeutics' score of 0.73 indicating that InflaRx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
InflaRx
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

InflaRx beats Maze Therapeutics on 8 of the 15 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IFRX vs. The Competition

MetricInflaRxPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$122.18M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-1.699.0626.8019.71
Price / Sales941.66251.66397.78120.67
Price / CashN/A65.8538.2534.62
Price / Book0.966.456.774.50
Net Income-$46.18M$143.98M$3.23B$248.22M
7 Day Performance9.64%0.38%0.48%-0.78%
1 Month Performance51.67%2.14%9.13%11.53%
1 Year Performance22.97%-0.33%18.58%8.99%

InflaRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IFRX
InflaRx
2.5585 of 5 stars
$1.82
+7.7%
$8.50
+367.0%
+11.7%$122.18M$129,752.00-1.6960
MAZE
Maze Therapeutics
N/A$10.13
+5.3%
$25.67
+153.4%
N/A$443.65M$167.50M0.00121Gap Up
SIGA
SIGA Technologies
1.1547 of 5 stars
$5.94
+4.9%
N/A-21.9%$424.36M$138.72M4.9540
ZVRA
Zevra Therapeutics
3.2348 of 5 stars
$7.75
-1.5%
$22.29
+187.6%
+85.1%$423.76M$23.61M-3.9320Analyst Upgrade
SAGE
Sage Therapeutics
3.9369 of 5 stars
$6.75
+2.9%
$8.81
+30.6%
-45.4%$410.79M$47.40M-1.02690
AMLX
Amylyx Pharmaceuticals
3.4374 of 5 stars
$4.60
-0.2%
$9.67
+110.1%
+192.9%$409.79M$-1,272,000.00-1.20200
PRTA
Prothena
3.853 of 5 stars
$7.61
+2.4%
$51.71
+579.6%
-69.7%$409.62M$137.94M-3.31130High Trading Volume
PRTC
PureTech Health
2.1304 of 5 stars
$17.03
+1.5%
$45.00
+164.3%
-40.1%$408.92M$4.32M0.00100Positive News
Gap Up
ABVX
ABIVAX Société Anonyme
2.44 of 5 stars
$6.40
-4.6%
$34.00
+431.3%
-57.7%$405.88MN/A0.0061
TRML
Tourmaline Bio
1.8449 of 5 stars
$15.78
+4.5%
$49.33
+212.6%
+12.0%$405.31MN/A-5.6044
PGEN
Precigen
3.3794 of 5 stars
$1.37
+3.0%
$7.00
+410.9%
+0.7%$404.38M$3.93M-2.49190Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:IFRX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners